Venture Friction: Why Breakthrough Neurotechnology So Often Fails to Reach Patients

Aidan Foley - 8th July, 2026

In January 2024, my wife Fiona suffered a cervical spinal cord injury. Overnight, our lives became immersed in a world of intensive care units, rehabilitation wards, wheelchairs, physiotherapy and occupational therapy. Like so many families entering that world for the first time, we encountered extraordinary clinicians - people working with skill, compassion and determination under immense pressure.

Yet alongside that admiration, another question slowly began to emerge. If neuroscience, robotics, virtual reality, artificial intelligence and brain-computer interfaces have advanced so dramatically over the past thirty years, why does rehabilitation for many people with catastrophic neurological injuries still feel so constrained by approaches that have changed remarkably little?

This isn’t a criticism of clinicians. They can only work with the tools available to them. Nor is it a criticism of science. The scientific progress has been extraordinary. The question is different.

Why is there such a large gap between what we appear capable of building and what patients actually experience? That question ultimately led to the creation of NEXR (an acronym of Neural Engineering and Extended Reality). It also led me to a broader conclusion.

The biggest barrier to progress may not be technological at all. It may be institutional. Introducing “Venture Friction”

Every breakthrough technology encounters friction. Sometimes it’s regulatory. Sometimes it’s technical. Sometimes it’s manufacturing. In neurotechnology, I believe there is another form that deserves far more attention: Venture Friction. By Venture Friction, I mean the structural mismatch between traditional investment models and the biological realities of neurological recovery.

Modern venture capital has transformed countless industries by funding ambitious ideas and helping them scale rapidly. It’s an extraordinarily successful model for many kinds of innovation. Neurological recovery, however, operates on very different timescales. Understanding the brain takes years. Building clinically robust systems takes years. Validating them safely takes years. Demonstrating meaningful functional recovery takes years. These biological realities don’t always align comfortably with investment models designed around rapid commercial milestones and relatively short exit horizons.

That isn’t anybody’s fault. It is simply a structural tension.

Building for Patients Rather Than Valuations

When we founded NEXR, we spent a long time thinking about this tension. Eventually we reached a conclusion that surprised even us. If our mission was genuinely to maximise long-term patient benefit, perhaps we should design the organisation itself around that objective.

Instead of creating another venture-backed startup, we established NEXR as an Irish Company Limited by Guarantee (CLG) - a not-for-profit structure with no shareholders and no exit strategy. That decision wasn’t ideological. It was architectural.

We wanted every major decision to answer the same question: “Does this improve outcomes for people living with neurological injury?” Not: “Does this improve the next funding round?” Commercial discipline still matters enormously. Engineering excellence still matters enormously. Financial sustainability still matters enormously. But they become servants of the mission rather than the mission itself.

A Different Definition of Success

Success in neurotechnology is often described through familiar metrics: valuation, fundraising, market share or acquisition. Those measures have their place, but they’re not the measures that matter most to the person sitting in a rehabilitation ward wondering whether they’ll ever regain movement, reduce chronic pain or recover independence. Patients measure success differently.
- Can I hold my child’s hand again?
- Can I dress myself?
- Can I sleep without neuropathic pain?
- Can I return to work?
- Can I reclaim part of the life I lost?

Those questions deserve to become engineering specifications.

Beyond Technology

NEXR is still at the beginning of its journey and, like every early-stage organisation, we have far more questions than answers. However one conviction has become increasingly clear - the future of neurorehabilitation won’t be determined solely by better algorithms, more sophisticated robotics or increasingly immersive virtual environments. It’ll also depend on whether we are willing to redesign the institutions that determine how those technologies are funded, validated and delivered.

If the next generation of neurotechnology is to fulfil its promise, we may need to innovate not only in engineering, but in the systems that surround engineering.

Technology changes remarkably quickly. Institutions often do not. Perhaps closing that gap is one of the most important engineering challenges of all.